Home › Funds › ARMISTICE CAPITAL, LLC › REGN

ARMISTICE CAPITAL, LLC position in REGN

REGENERON PHARMACEUTICALS · Health Care

ARMISTICE CAPITAL, LLC reported holding 89,809 shares of REGN (REGENERON PHARMACEUTICALS) in its Q2 2026 13F filing — a position valued at US$56.0M, representing 0.74% of its reported portfolio and ranking #17 among its reported holdings. ARMISTICE CAPITAL, LLC has disclosed REGN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)89.81K sh
Reported value held$56.00M
Portfolio Weight0.74%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How ARMISTICE CAPITAL, LLC's REGN position evolved

ARMISTICE CAPITAL, LLC first disclosed a stake in REGN in Q3 2023 at 74,998 shares (US$61.7M). The position peaked in Q1 2025 at 114,073 shares, worth US$72.3M. Across 12 filings, ARMISTICE CAPITAL, LLC increased the stake 5 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 89,809 shares valued at US$56.0M — an increase of 53,683 shares quarter over quarter.. Notable position changes include a 66% increase in Q3 2024 (shares fell 32% over the following quarter), a 307% increase in Q1 2025 (shares fell 17% over the following quarter), a 149% increase in Q2 2026 (shares rose 22% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 75.00K $61.72M New
Q4 2023 60.00K $52.70M Reduce
Q1 2024 22.99K $22.12M Reduce
Q2 2024 12.06K $12.68M Reduce
Q3 2024 20.03K $21.06M Add
Q4 2024 28.05K $19.98M Add
Q1 2025 114.07K $72.35M Add
Q2 2025 100.03K $52.52M Reduce
Q3 2025 125.21K $70.40M Add
Q4 2025 84.00K $64.84M Reduce
Q1 2026 36.13K $27.91M Reduce
Q2 2026 89.81K $56.00M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About REGN and 13F data

REGN (REGENERON PHARMACEUTICALS) is a Health Care company. 31 other funds we track also report a position in REGN — the largest reported positions include Dodge & Cox (US$3.04B), DODGE & COX (US$3.04B), LOOMIS SAYLES & CO L P (US$1.16B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding REGN

All REGN fund holders →

FAQ

How long has ARMISTICE CAPITAL, LLC held REGN?

ARMISTICE CAPITAL, LLC has disclosed REGN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is ARMISTICE CAPITAL, LLC's current position in REGN?

As of Q2 2026, ARMISTICE CAPITAL, LLC holds 89.81K shares of REGN (REGENERON PHARMACEUTICALS), valued at $56.00M, representing 0.74% of its reported portfolio and ranking #17.

Has ARMISTICE CAPITAL, LLC been buying or selling REGN?

In the latest 13F filing (Q2 2026), ARMISTICE CAPITAL, LLC increased its position in REGN. The position peaked in Q1 2025 at 114.07K shares.

Which other funds hold REGN?

Other major institutional holders of REGN include Dodge & Cox, DODGE & COX, LOOMIS SAYLES & CO L P, among 31 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.